韩国多中心前瞻性队列研究主动监测或手术(KoMPASS)治疗甲状腺乳头状微癌的方案。

Endocrinology and metabolism (Seoul, Korea) Pub Date : 2021-04-01 Epub Date: 2021-03-23 DOI:10.3803/EnM.2020.890
Min Ji Jeon, Yea Eun Kang, Jae Hoon Moon, Dong Jun Lim, Chang Yoon Lee, Yong Sang Lee, Sun Wook Kim, Min-Hee Kim, Bo Hyun Kim, Ho-Cheol Kang, Minho Shong, Sun Wook Cho, Won Bae Kim
{"title":"韩国多中心前瞻性队列研究主动监测或手术(KoMPASS)治疗甲状腺乳头状微癌的方案。","authors":"Min Ji Jeon,&nbsp;Yea Eun Kang,&nbsp;Jae Hoon Moon,&nbsp;Dong Jun Lim,&nbsp;Chang Yoon Lee,&nbsp;Yong Sang Lee,&nbsp;Sun Wook Kim,&nbsp;Min-Hee Kim,&nbsp;Bo Hyun Kim,&nbsp;Ho-Cheol Kang,&nbsp;Minho Shong,&nbsp;Sun Wook Cho,&nbsp;Won Bae Kim","doi":"10.3803/EnM.2020.890","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A Korean Multicenter Prospective cohort study of Active Surveillance or Surgery (KoMPASS) for papillary thyroid microcarcinomas (PTMCs) has been initiated. The aim is to compare clinical outcomes between active surveillance (AS) and an immediate lobectomy for low-risk PTMCs. We here outline the detailed protocol for this study.</p><p><strong>Methods: </strong>Adult patients with a cytopathologically confirmed PTMC sized 6.0 to 10.0 mm by ultrasound (US) will be included. Patients will be excluded if they have a suspicious extra-thyroidal extension or metastasis of a PTMC or multiple thyroid nodules or other thyroid diseases which require a total thyroidectomy. Printed material describing the prognosis of PTMCs, and the pros and cons of each management option, will be provided to eligible patients to select their preferred intervention. For the AS group, thyroid US, thyroid function, and quality of life (QoL) parameters will be monitored every 6 months during the first year, and then annually thereafter. Disease progression will be defined as a ≥3 mm increase in maximal diameter of a PTMC, or the development of new thyroid cancers or metastases. If progression is detected, patients should undergo appropriate surgery. For the lobectomy group, a lobectomy with prophylactic central neck dissection will be done within 6 months. After initial surgery, thyroid US, thyroid function, serum thyroglobulin (Tg), anti-Tg antibody, and QoL parameters will be monitored every 6 months during the first year and annually thereafter. Disease progression will be defined in these cases as the development of new thyroid cancers or metastases.</p><p><strong>Conclusion: </strong>KoMPASS findings will help to confirm the role of AS, and develop individualized management strategies, for low-risk PTMCs.</p>","PeriodicalId":520607,"journal":{"name":"Endocrinology and metabolism (Seoul, Korea)","volume":" ","pages":"359-364"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f5/0d/enm-2020-890.PMC8090471.pdf","citationCount":"11","resultStr":"{\"title\":\"Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma.\",\"authors\":\"Min Ji Jeon,&nbsp;Yea Eun Kang,&nbsp;Jae Hoon Moon,&nbsp;Dong Jun Lim,&nbsp;Chang Yoon Lee,&nbsp;Yong Sang Lee,&nbsp;Sun Wook Kim,&nbsp;Min-Hee Kim,&nbsp;Bo Hyun Kim,&nbsp;Ho-Cheol Kang,&nbsp;Minho Shong,&nbsp;Sun Wook Cho,&nbsp;Won Bae Kim\",\"doi\":\"10.3803/EnM.2020.890\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>A Korean Multicenter Prospective cohort study of Active Surveillance or Surgery (KoMPASS) for papillary thyroid microcarcinomas (PTMCs) has been initiated. The aim is to compare clinical outcomes between active surveillance (AS) and an immediate lobectomy for low-risk PTMCs. We here outline the detailed protocol for this study.</p><p><strong>Methods: </strong>Adult patients with a cytopathologically confirmed PTMC sized 6.0 to 10.0 mm by ultrasound (US) will be included. Patients will be excluded if they have a suspicious extra-thyroidal extension or metastasis of a PTMC or multiple thyroid nodules or other thyroid diseases which require a total thyroidectomy. Printed material describing the prognosis of PTMCs, and the pros and cons of each management option, will be provided to eligible patients to select their preferred intervention. For the AS group, thyroid US, thyroid function, and quality of life (QoL) parameters will be monitored every 6 months during the first year, and then annually thereafter. Disease progression will be defined as a ≥3 mm increase in maximal diameter of a PTMC, or the development of new thyroid cancers or metastases. If progression is detected, patients should undergo appropriate surgery. For the lobectomy group, a lobectomy with prophylactic central neck dissection will be done within 6 months. After initial surgery, thyroid US, thyroid function, serum thyroglobulin (Tg), anti-Tg antibody, and QoL parameters will be monitored every 6 months during the first year and annually thereafter. Disease progression will be defined in these cases as the development of new thyroid cancers or metastases.</p><p><strong>Conclusion: </strong>KoMPASS findings will help to confirm the role of AS, and develop individualized management strategies, for low-risk PTMCs.</p>\",\"PeriodicalId\":520607,\"journal\":{\"name\":\"Endocrinology and metabolism (Seoul, Korea)\",\"volume\":\" \",\"pages\":\"359-364\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f5/0d/enm-2020-890.PMC8090471.pdf\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinology and metabolism (Seoul, Korea)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3803/EnM.2020.890\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/3/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology and metabolism (Seoul, Korea)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3803/EnM.2020.890","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/23 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

摘要

背景:韩国一项针对乳头状甲状腺微癌(PTMCs)的主动监测或手术(KoMPASS)的多中心前瞻性队列研究已经启动。目的是比较主动监测(AS)和立即肺叶切除术对低风险ptmc的临床结果。我们在此概述本研究的详细方案。方法:通过超声(US)细胞病理学证实的PTMC大小为6.0至10.0 mm的成年患者将被纳入。如果患者有可疑的甲状腺外延伸或转移的PTMC或多发性甲状腺结节或其他甲状腺疾病,需要全甲状腺切除术,将被排除在外。将向符合条件的患者提供描述ptmc预后的印刷材料,以及每种管理方案的优缺点,以选择他们首选的干预措施。对于AS组,第一年每6个月监测甲状腺US、甲状腺功能和生活质量(QoL)参数,之后每年监测一次。疾病进展将被定义为PTMC最大直径增加≥3mm,或出现新的甲状腺癌或转移。如果发现进展,患者应接受适当的手术。肺叶切除术组在6个月内行肺叶切除术并预防性中央颈部清扫术。术后第一年每6个月监测一次甲状腺US、甲状腺功能、血清甲状腺球蛋白(Tg)、抗Tg抗体、生活质量参数,术后每年监测一次。在这些病例中,疾病进展将被定义为新的甲状腺癌或转移的发展。结论:KoMPASS的研究结果将有助于确认AS的作用,并为低风险ptmc制定个性化的管理策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma.

Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma.

Background: A Korean Multicenter Prospective cohort study of Active Surveillance or Surgery (KoMPASS) for papillary thyroid microcarcinomas (PTMCs) has been initiated. The aim is to compare clinical outcomes between active surveillance (AS) and an immediate lobectomy for low-risk PTMCs. We here outline the detailed protocol for this study.

Methods: Adult patients with a cytopathologically confirmed PTMC sized 6.0 to 10.0 mm by ultrasound (US) will be included. Patients will be excluded if they have a suspicious extra-thyroidal extension or metastasis of a PTMC or multiple thyroid nodules or other thyroid diseases which require a total thyroidectomy. Printed material describing the prognosis of PTMCs, and the pros and cons of each management option, will be provided to eligible patients to select their preferred intervention. For the AS group, thyroid US, thyroid function, and quality of life (QoL) parameters will be monitored every 6 months during the first year, and then annually thereafter. Disease progression will be defined as a ≥3 mm increase in maximal diameter of a PTMC, or the development of new thyroid cancers or metastases. If progression is detected, patients should undergo appropriate surgery. For the lobectomy group, a lobectomy with prophylactic central neck dissection will be done within 6 months. After initial surgery, thyroid US, thyroid function, serum thyroglobulin (Tg), anti-Tg antibody, and QoL parameters will be monitored every 6 months during the first year and annually thereafter. Disease progression will be defined in these cases as the development of new thyroid cancers or metastases.

Conclusion: KoMPASS findings will help to confirm the role of AS, and develop individualized management strategies, for low-risk PTMCs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信